APA (7th ed.) Citation

Liu, J., Lan, C., Liu, T., Liu, Q., Chang, L., Zang, L., . . . Xu, Q. (2025). Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer. BMC Medicine, 23(1), 1. https://doi.org/10.1186/s12916-025-04198-5

Chicago Style (17th ed.) Citation

Liu, Jing, et al. "Long-term Efficacy and Updated Survival Outcomes of Sintilimab Plus Anlotinib in Patients with PD-L1-positive Recurrent or Metastatic Cervical Cancer." BMC Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12916-025-04198-5.

MLA (9th ed.) Citation

Liu, Jing, et al. "Long-term Efficacy and Updated Survival Outcomes of Sintilimab Plus Anlotinib in Patients with PD-L1-positive Recurrent or Metastatic Cervical Cancer." BMC Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12916-025-04198-5.